The purpose of this course is to provide clinicians and scientists with an updated overview of the spectrum of lymphoid leukemias including ALL, CLL, and HCL. There will be ample time for questions and discussions throughout the day. The educational objectives of this course are as follows:
- Improve the understanding of contemporary treatments for ALL, CLL, and HCL, particularly with regards to immunotherapy and kinase inhibitor therapies.
- Gain insight into experimental therapeutic options for patients with these disorders including novel immunotherapeutic approaches, transplantation, and small molecule inhibitors.
Recognize the key molecular drivers of ALL, CLL, and HCL as well as appropriate testing for response and resistance to therapy
This course is directed towards physicians and allied health professionals who care for patients with lymphoid malignancies including Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL) and/or small lymphocytic lymphoma (SLL), and Hairy Cell Leukemia (HCL.)
Memorial Sloan-Kettering Cancer is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Memorial Sloan-Kettering Cancer Center designates this educational activity for a maximum of 6.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.